Research In Brief
This article was originally published in The Gray Sheet
Executive Summary
Drug-coated angioplasty balloon: Percutaneous treatment of femoropopliteal disease with paclitaxel-coated angioplasty balloons was associated with reduced six-month lumen loss and target-lesion revascularization rates compared to regular angioplasty balloons in the 154-patient randomized THUNDER trial sponsored by Bavaria Medizintechnologie and Schering. Results appear in the Feb. 14 issue of the New England Journal of Medicine. THUNDER is a small preliminary study and larger trials are needed to confirm the benefits of drug-coated balloons, according to authors Gunnar Tepe, M.D., University of Tübingen, et al
You may also be interested in...
Startups Persevere Toward Gaining Artificial Liver Approval
The potential market opportunity for an artificial liver keeps players in the game, even though many companies have tried and failed in the past
Startups Persevere Toward Gaining Artificial Liver Approval
The potential market opportunity for an artificial liver keeps players in the game, even though many companies have tried and failed in the past
Cardiology Conference: “Practice-Changing” Data On Device Interventions
Late-breaking clinical trials of coronary stent and related interventions are bringing both practice-changing and surprising results, according to physicians who attended a major cardiology meeting in Chicago last week